The substantial comorbidity burdenapproximately 30% of inflammatory bowel disease patients develop anxiety or depressionhighlights the urgent need for dual-effect therapies that simultaneously address intestinal inflammation and gut-brain axis modulation
In the TRANSCEND-T2D-1 trial (published in The Lancet , June 2026), individuals with type 2 diabetes lost -15.3% at 12 mg over 40 weeks
Before discussing these medications with a healthcare provider, individuals should consider their weight loss goals, current health status, and any existing medical conditions
Do you really know what youre injecting into your body? the ad asks readers of USA Today and the New York Times
Keeping a food diary for two weeks often reveals surprising connections between specific meals and worse nights
Every filler plan starts with a facial analysis, not a menu